tbuckley/cabot-search huggingface dataset:
Annals On Being a Doctor Story Slam - Two More Days
Authors: Jenni Levy
Journal: Annals of Internal Medicine (2016)

Web Exclusives19 January 2016Annals On Being a Doctor Story Slam - Two More DaysFREEJenni Levy, MDJenni Levy, MDFrom St. Luke's Hospice, Bethlehem, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/V15-0015 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals On Being a Doctor Story Slam - Two More Days This story, "Two More Days," by Dr. Jenni Levy, is from the Annals On Being a Doctor Story Slam held on 18 November 2015 in Philadelphia, with support from the Josiah Macy Jr. Foundation (Duration 6:09)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals On Being a Doctor Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From St. Luke's Hospice, Bethlehem, Pennsylvania.Note:This story is from the Annals On Being a Doctor Story Slam held on 18 November 2015 in Philadelphia, with support from the Josiah Macy Jr. Foundation.Corresponding Author: Jenni Levy, MD, St. Luke's Hospice, 2455 Black River Road, Bethlehem, PA 18015; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 January 2016Volume 164, Issue 2Page: SS4KeywordsRivers ePublished: 19 January 2016 Issue Published: 19 January 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.Loading ...
α-Fetoprotein in Monkeys With Hepatoma&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Edgar W. Hull, Paul P. Carbone, David Gitlin, Roger W. O'Gara, Margaret G. Kelly
Journal: JNCI Journal of the National Cancer Institute (1969)

Of 42 monkeys treated with N-nitrosodiethylamine (DENA) for at least 1 year, 23 developed hepatoma. Serum α-fetoprotein (αFP) was found in 20 (87%) of these 23 monkeys, but was not detected in any of the 19 without hepatoma or in any of 75 other monkeys which did not develop hepatoma after treatment with other chemical agents. Liver function tests revealed abnormalities in 78% of the animals with hepatoma and 36% of the 94 monkeys without hepatoma. In a prospective study, 9 of 14 monkeys developing hepatoma had positive αFP assays either before or at the time hepatic nodules first became palpable. There was no evident correlation between the appearance of serum αFP and the size or cellular differentiation of the hepatomas. In 4 of 6 monkeys, αFP-negative at initial biopsy diagnosis of hepatoma, a heavy lymphocytic infiltration was noted in or around the tumor tissue.
How to get patients' consent to enter clinical trials
Authors: F A. I Riordan, A. P J Thomson
Journal: BMJ (1996)

therefore the use of the term emergency contraception for early abortion is erroneous.According to the datasheet, "Schering PC4 is primarily aimed to prevent implantation of the fertilised ovum in the endometrium."Insertion of a foreign body such as an intrauterine contraceptive device achieves the same effect.
Moderate drinking also improves health
Authors: R. A Lyons, S. Vuilo, S. Monaghan, B. N C Littlepage
Journal: BMJ (1995)

consumption carries no benefit in terms of mortality.Pending further studies, it would be prudent from a health promotion perspective not to advocate alcohol consumption as a procedure for extending life but to assume that the dose-response relation for mortality and alcohol consumption is linear with a positive slope.
Guidelines for the use of local anesthesia in office-based dermatologic surgery
Authors: David J. Kouba, Matteo C. LoPiccolo, Murad Alam, Jeremy S. Bordeaux, Bernard Cohen, C. William Hanke, Nathaniel Jellinek, Howard I. Maibach, Jonathan W. Tanner, Neelam Vashi, Kenneth G. Gross, Trudy Adamson, Wendy Smith Begolka, Jose V. Moyano
Journal: Journal of the American Academy of Dermatology (2016)
TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
Authors: Licia Rivoltini, Claudia Chiodoni, Paola Squarcina, Monica Tortoreto, Antonello Villa, Barbara Vergani, Maja Bürdek, Laura Botti, Ivano Arioli, Agata Cova, Giorgio Mauri, Elisabetta Vergani, Beatrice Bianchi, Pamela Della Mina, Laura Cantone, Valentina Bollati, Nadia Zaffaroni, Alessandro Massimo Gianni, Mario Paolo Colombo, Veronica Huber
Journal: Clinical Cancer Research (2016)

Exosomes deliver signals to target cells and could thus be exploited as an innovative therapeutic tool. We investigated the ability of membrane TRAIL-armed exosomes to deliver proapoptotic signals to cancer cells and mediate growth inhibition in different tumor models.K562 cells, transduced with lentiviral human membrane TRAIL, were used for the production of TRAIL(+) exosomes, which were studied by nanoparticle tracking analysis, cytofluorimetry, immunoelectronmicroscopy, Western blot, and ELISA. In vitro, TRAIL(+) exosomes induced more pronounced apoptosis (detected by Annexin V/propidium iodide and activated caspase-3) in TRAIL-death receptor (DR)5(+) cells (SUDHL4 lymphoma and INT12 melanoma), with respect to the DR5(-)DR4(+)KMS11 multiple myeloma. Intratumor injection of TRAIL(+) exosomes, but not mock exosomes, induced growth inhibition of SUDHL4 (68%) and INT12 (51%), and necrosis in KMS11 tumors. After rapid blood clearance, systemically administered TRAIL(+) exosomes accumulated in the liver, lungs, and spleen and homed to the tumor site, leading to a significant reduction of tumor growth (58%) in SUDHL4-bearing mice. The treatment of INT12-bearing animals promoted tumor necrosis and a not statistically significant tumor volume reduction. In KMS11-bearing mice, despite massive perivascular necrosis, no significant tumor growth inhibition was detected.TRAIL-armed exosomes can induce apoptosis in cancer cells and control tumor progression in vivo Therapeutic efficacy was particularly evident in intratumor setting, while depended on tumor model upon systemic administration. Thanks to their ability to deliver multiple signals, exosomes thus represent a promising therapeutic tool in cancer. Clin Cancer Res; 22(14); 3499-512. ©2016 AACR.
Sequential imatinib and chemotherapy yield reverse-transcriptase polymerase chain reaction (RT-PCR)-negative peripheral stem cell collections in Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL)—Preliminary results of CALGB 10001
Authors: M. Wetzler, W. Stock, K. Owzar, D. A. Sher, E. E. Hoke, C. A. Linker, C. D. Bloomfield, R. A. Larson
Journal: Journal of Clinical Oncology (2006)

6549 Background: Ph+ ALL has a short complete remission duration and survival. Allogeneic stem cell transplantation (SCT) is recommended. We hypothesized that imatinib plus sequential chemotherapy will result in greater leukemia cell cytoreduction than previously achieved with chemotherapy alone, allowing collection of large numbers of normal hematopoietic stem cells uncontaminated by residual t(9;22) lymphoblasts and thus reduce the likelihood of relapse after autologous SCT for patients without donors. Methods: Treatment consisted of a 4–5 drug induction regimen followed by imatinib 400 mg BID for 4 weeks, CNS prophylaxis with high-dose methotrexate, another month of imatinib, and ideally allogeneic SCT following fractionated total body irradiation (FTBI) and etoposide. Those without donors received high-dose cytarabine, etoposide, and G-CSF for stem cell mobilization, leukapheresis, and autologous SCT after FTBI, etoposide and cyclophosphamide. Imatinib maintenance continues until RT-PCR negative for 12 months. Patients had to be &lt; 60 years old. Results: 18 patients have enrolled to date; so far 3 underwent allogeneic SCT and 5 completed peripheral stem cell collections of whom 4 have undergone autologous SCT. Median stem cell yield was 55.74×10 6 /kg (range, 34.8–94.4). Peripheral stem cells were assayed from 3 patients for RT-PCR with a sensitivity of 1:10 5 -10 6 . All 3 samples were negative for BCR-ABL. Of the 3 patients who underwent allogeneic SCT, 1 failed to engraft and died, 1 died due to respiratory failure on day 70, and 1 relapsed on day 113. Of the 4 patients who underwent autologous SCT, all achieved neutrophil engraftment (&gt; 0.5×10 9 /L) between days 8–10 and platelet engraftment (&gt; 50×10 9 /L) between days 7–17. Two patients relapsed (simultaneous CNS and marrow) on days 164 and 309, and 2 patients are alive in continuous remission on days +297 and +359 following autologous SCT. Conclusions: Sequential imatinib and chemotherapy can achieve RT-PCR negativity in Ph+ ALL, allowing autologous SCT. Ongoing accrual will evaluate the efficacy of this approach in adults with Ph+ ALL. [Table: see text]
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
Authors: J C Ruckdeschel, D M Finkelstein, D S Ettinger, R H Creech, B A Mason, R A Joss, S Vogl
Journal: Journal of Clinical Oncology (1986)

Between October 1981 and June 1983, the Eastern Cooperative Oncology Group (ECOG) conducted a prospectively randomized trial (EST 1581) of the four most active chemotherapy regimens for metastatic non-small-cell lung cancer (NSCLC). Four hundred eighty-six good performance status patients (PS 0 or 1; 81%) were randomized to receive cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP); mitomycin, vinblastine, and cisplatin (MVP); etoposide and cisplatin (VP-P); or vindesine and cisplatin (VDA-P). All regimens were administered in the doses and schedules originally reported. Complete response (CR) plus partial response (PR) rates for the four regimens were CAMP, 17%; MVP, 31%; VP-P, 20%; and VDA-P, 25%. The response rate for MVP was significantly higher in patients with squamous and adenocarcinoma histologies, but there was no impact on median survival (overall, 24.5 weeks). The duration of response did not differ by treatment as previously suggested for VDA-P. There were 15 CRs (CAMP, one; MVP, six; VP-P, two; VDA-P, six), and 12 patients have survived more than 2 years. Toxicity was significant with 20 treatment-related deaths. CAMP was significantly less toxic than the other regimens (P less than .001). VDA-P demonstrated significantly more life-threatening (seven) and lethal (three) episodes of nephrotoxicity (P less than .001) despite an aggressive hydration program that in itself caused significant morbidity. Analysis of the toxicity data showed, however, that most of the severe toxicity occurred in the 19% of patients who were initially PS 2, suggesting that they are not appropriate candidates for trials of new agents or combinations. None of these regimens can be recommended as a standard therapy for metastatic NSCLC.
Analysis of KIR Framework Loci in Patients with NK-Type Lymphoproliferative Disease of Granular Lymphocytes (LDGL).
Authors: Renato Zambello, Elisa Scquizzato, Antonella Teramo, Monica Facco, Laura Pavan, Marta Miorin, Livio Trentin, Carlo Agostini, Gianpietro Semenzato
Journal: Blood (2005)
Mitochondria in lung disease
Authors: Suzanne M. Cloonan, Augustine M.K. Choi
Journal: Journal of Clinical Investigation (2016)

Mitochondria are a distinguishing feature of eukaryotic cells. Best known for their critical function in energy production via oxidative phosphorylation (OXPHOS), mitochondria are essential for nutrient and oxygen sensing and for the regulation of critical cellular processes, including cell death and inflammation. Such diverse functional roles for organelles that were once thought to be simple may be attributed to their distinct heteroplasmic genome, exclusive maternal lineage of inheritance, and ability to generate signals to communicate with other cellular organelles. Mitochondria are now thought of as one of the cell’s most sophisticated and dynamic responsive sensing systems. Specific signatures of mitochondrial dysfunction that are associated with disease pathogenesis and/or progression are becoming increasingly important. In particular, the centrality of mitochondria in the pathological processes and clinical phenotypes associated with a range of lung diseases is emerging. Understanding the molecular mechanisms regulating the mitochondrial processes of lung cells will help to better define phenotypes and clinical manifestations associated with respiratory disease and to identify potential diagnostic and therapeutic targets.
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
Authors: Sofie Wilgenhof, Jurgen Corthals, Carlo Heirman, Nicolas van Baren, Sophie Lucas, Pia Kvistborg, Kris Thielemans, Bart Neyns
Journal: Journal of Clinical Oncology (2016)

Autologous monocyte-derived dendritic cells (DCs) electroporated with synthetic mRNA (TriMixDC-MEL) are immunogenic and have antitumor activity as a monotherapy in patients with pretreated advanced melanoma. Ipilimumab, an immunoglobulin G1 monoclonal antibody directed against the cytotoxic T-lymphocyte-associated protein 4 receptor that counteracts physiologic suppression of T-cell function, improves the overall survival of patients with advanced melanoma. This phase II study investigated the combination of TriMixDC-MEL and ipilimumab in patients with pretreated advanced melanoma.Thirty-nine patients were treated with TriMixDC-MEL (4 × 10(6) cells administered intradermally and 20 × 10(6) cells administered intravenously) plus ipilimumab (10 mg/kg every 3 weeks for a total of four administrations, followed by maintenance therapy every 12 weeks in patients who remained progression free). Six-month disease control rate according to the immune-related response criteria served as the primary end point.The 6-month disease control rate was 51% (95% CI, 36% to 67%), and the overall tumor response rate was 38% (including eight complete and seven partial responses). Seven complete responses and one partial tumor response are ongoing after a median follow-up time of 36 months (range, 22 to 43 months). The most common treatment-related adverse events (all grades) consisted of local DC injection site skin reactions (100%), transient post-DC infusion chills (38%) and flu-like symptoms (84%), dermatitis (64%), hepatitis (13%), hypophysitis (15%), and diarrhea/colitis (15%). Grade 3 or 4 immune-related adverse events occurred in 36% of patients. There was no grade 5 adverse event.The combination of TriMixDC-MEL and ipilimumab is tolerable and results in an encouraging rate of highly durable tumor responses in patients with pretreated advanced melanoma.
Abstract 9714: The Impact of Chronic Kidney Disease on Complications and All-Cause Mortality After Implantable Device Replacement or Upgrade: Survival Analyses From the REPLACE Registry
Authors: Suneet Mittal, Mina K Chung, Jonathan S Steinberg, Richard Holcomb, Marye J Gleva, Kevin Mitchell, Jeanne E Poole
Journal: Circulation (2012)

Background: Chronic kidney disease (CKD) increases the risk for a variety of arrhythmias and these patients often require cardiac implantable electronic device (CIED) implantation. We sought to assess the impact of CKD on complications and mortality in REPLACE. Methods: REPLACE was a prospective registry of patients undergoing CIED replacement without or with the intent to add or revise one or more leads. CKD stage was based on the National Kidney Foundation classification: stage 1, normal GFR 90; stage 2, GFR 69-89; stage 3, GFR 30-59; stage 4, GFR 15-29; stage 5, GFR &lt;15 or on renal dialysis. The 6-month complication rate and mortality was determined. Results: GFR data were available in 1662 (95%) of 1744 patients; by 6-months of follow-up, 254 (15%) of these patients experienced a complication and 67 (4%) patients died. CKD stage did not significantly impact the likelihood of patients experiencing a complication. Cox multivariate analysis identified 5 predictors of survival: prior admission for heart failure (HR 3.05; 95% CI 1.76-5.26), NYHA class III/IV (HR 1.87; 95% CI: 1.07-3.25), antiarrhythmic drug use (HR 1.80; 95% CI: 1.08-2.98), cerebrovascular disease (HR 1.90; 95% CI: 1.11-3.25), and CKD stage (HR 1.5; 95% CI: 1.12-2.0). Patients with stage I-II CKD had a 2.4% 6-month all-cause mortality. In comparison, the mortality was more than 2-fold higher in stage III patients (5.3%), 3-fold higher in stage IV patients (8.6%), and 6-fold higher in stage V patients (16.0%) (Figure). Conclusions: In this prospective registry, CKD was an independent and potent risk factor for mortality. The increase in mortality as a function of CKD stage became evident by the first month following the CIED procedure. Importantly, the excess mortality was not driven by procedure-related complications. Future investigation needs to be directed towards identification of the mechanisms of death and methods to reduce mortality in patients with CKD who undergo CIED replacement.
Surgical Mesh Should Be Made Affordable to Low- and Middle-Income Countries
Authors: Joseph D. Forrester, Jared A. Forrester, George P. Yang
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Pulmonary nodules: bringing order out of chaos
Authors: Angela Morgan, Mark Slade
Journal: Thorax (2015)

Picture the scene: a lung cancer multidisciplinary team (MDT) meeting, somewhere in the UK, January 2015. CT images from a patient with suspected colorectal cancer, whom no one present has ever met, are discussed at the request of the colorectal team. An abnormality is present in the right lower lobe of lung. A week earlier, following two clicks and a drag from the colorectal radiologist's mouse, a 5 mm incidental pulmonary nodule was identified and is now destined to take its unwitting host on an unpredictable journey, which may span years. Imperfectly remembered advice from multiple professional society guidelines, some a decade old, will be proffered and contested in repeated meetings. How should the nodule be measured, how often, by whom? What is the risk that it is malignant? Is now (ever?) the right time for a biopsy? This scenario, which is likely familiar to many readers, has often served to relegate nodule follow-up to a tedious chore shared widely to ease the burden.

Help is at hand. With this issue of Thorax, David Baldwin, Mat Callister and colleagues publish the British Thoracic Society (BTS) guidelines for the investigation and management of pulmonary nodules,1 together with their own clear summary,2 which will support good, evidence-based patient care, effective resource use and audited outcomes. The precise and detailed distillation of a burgeoning evidence base—one-third of the 360 references are from 2012 or later—into four graphic algorithms represents a huge step from chaos towards order. It offers chest physicians everywhere the opportunity to channel the growing number of patients with incidental pulmonary nodules into a consistent and systematic process of investigation and, where appropriate, treatment.

A number of helpful simplifications emerge. Data from several large screening studies, including the Dutch NELSON study,3 provide clear evidence that nodules …
Sexual dysfunctions and psychoanalysis
Authors: E M Levine, N Ross
Journal: American Journal of Psychiatry (1977)

The authors examine the major factors involved in recent changes in the social standards and attitudes related to homosexuality. The principal influences investigated include the misconstrued emphasis given to the humanist ideology, which properly stresses the dignity of the individual; the social sciences' relativization of the cultural norms defining homosexuality; the influence of the mass media in disseminating these perspectives and thereby tending to create an acceptable image of homosexuality, and the tendency of all these changes to result in a substantial increase in public acceptance and tolerance of homosexuality. The authors suggest that this trend in public opinion has begun to isolate psychoanalytic knowledge, to reduce its status and acceptability among the public, and to replace it with popular views concerning the meaning of sexual dysfunctions.
Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases
Authors: Mathieu Leclerc, Felipe Suarez, Marie-Pierre Noël, Anne Vekhoff, Xavier Troussard, Jean-François Claisse, Catherine Thieblemont, Frédéric Maloisel, Yves Beguin, Jérôme Tamburini, Coralie Barbe, Alain Delmer
Journal: Blood (2013)
Chromosome 9p21 Polymorphism Interacts With Waist-to-Hip Ratio in Carotid Plaque
Authors: Ian Buysschaert, Ernst Rietzschel, Natacha Lays, Bart Claes, Sofie Bekaert, Peter Verhamme, Patrick Segers, Tim De Meyer, Dirk De Bacquer, Thierry Gillebert, Marc De Buyzere, Diether Lambrechts
Journal: Circulation (2009)

Background: A gene-environment interaction has been suggested between a chromosome 9p21 polymorphism, which confers a major risk for cardiovascular disease, and waist-to-hip ratio (WHR). We further characterized this interaction for carotid atherosclerosis in the larger population-based Asklepios study. 

Methods and Results: We genotyped the rs1333049 polymorphism on chromosome 9p21 in 2,481 healthy individuals aged 35 to 55 years, in which atherosclerotic plaque and intima-media thickness (IMT) were measured in both carotid arteries by a single investigator. We found that the rs1333049 C risk-allele was significantly associated with plaque in carotid arteries in both age- and gender-adjusted and multivariable-adjusted models (Table). No association was seen with IMT. Interestingly, rs1333049 interacted significantly with WHR (P-values of interaction for plaque in left, right and bilateral carotid arteries, respectively, corrected for age and gender: P=0.029; 0.051 and 0.004; multivariable adjusted: P= 0.035; 0.020 and 0.002). Stratification of the cohort according to a WHR equal to or above and below the mean (0.78 for women and 0.92 for men), showed that the risk effect of rs1333049 was confined to abdominal obese individuals only (Table). Stratification by WHO abdominal obesity criteria yielded similar results. No significant interaction was seen for IMT. 

Conclusion: We confirm the interaction between the rs1333049 polymorphism on 9p21 and WHR and demonstrate that the rs1333049 risk-allele increases carotid plaque in abdominal obese individuals only. With the prevalence of obesity increasing rapidly, this interaction is of importance for cardiovascular disease. 


Table: Carotid plaque frequencies and odds ratios per rs1333049 C-risk allele for the total cohort and after stratification for WHR.
Heregulin as a Biomarker for Anti-Her3 Antibody Patritumab Combined with Erlotinib in Non-Small Cell Lung Cancer
Authors: Kimio Yonesaka, Hisato Kawakami, Hiroyasu Kaneda, Isamu Okamoto, Kenji Hirotani, Kazuto Nishio, Kazuhiko Nakagawa
Journal: Annals of Oncology (2014)